Climber towards the summit of neuroimmunology——Professor Hao Junwei

doi:10.3969/j.issn.1006-7795.2020.05.008

Abstract

Abstract: Professor Hao Junwei is the winner of the National Science Fund for Distinguished Young Scholars, the top-notch young talent of the National "Ten Thousand Talents Program", and he was selected into the "New Century Excellent Talents Support Program" of the Ministry of Education. With experienced clinical practice and proficient scientific research, he achieves in the area of immuno-inflammatory and translational medicine of neurological diseases. His diligent, pioneering, and innovative quality represents the enterprising spirit of the new generation of Capital Medical University.

Key words: neuroimmune diseases, stroke, neuroinflammation, natural killer cells

CLC Number:

R503
R74.3

Wang Fei, Liu Haijie, Yang Jia, Liu Zheng, Hao Junwei. Climber towards the summit of neuroimmunology——Professor Hao Junwei[J]. Journal of Capital Medical University, 2020, 41(5): 763-767.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.05.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I5/763

References

[1] Hao J W, Liu R L, Piao W H, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology[J]. J Exp Med, 2010, 207(9):1907-1921.
[2] Hao J W, Campagnolo D, Liu R L, et al. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation[J]. Ann Neurol 2011, 69(4):721-734.
[3] Jiang W, Li D J, Han R R, et al. Acetylcholine-producing NK cells attenuate CNS inflammation via modulation of infiltrating monocytes/macrophages[J]. Proc Natl Acad Sci U S A, 2017, 114(30):E6202-E6211.
[4] Han B, Li X P, Hao J W. The cholinergic anti-inflammatory pathway:An innovative treatment strategy for neurological diseases[J]. Neurosci Biobehav Rev, 2017, 77:358-368.
[5] Ding Y N, Han R R, Jiang W, et al. Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats[J]. J Immunol, 2016, 197(10):3831-3840.
[6] Jiang W, St-Pierre S, Roy P, et al. Infiltration of CCR2⁺Ly6C^high proinflammatory monocytes and neutrophils into the central nervous system is modulated by nicotinic acetylcholine receptors in a model of multiple sclerosis[J]. J Immunol, 2016, 196(5):2095-2108.
[7] Liu R Q, Ma X F, Chen L, et al. MicroRNA-15b suppresses Th17 differentiation and is associated with pathogenesis of multiple sclerosis by targeting O-GlcNAc transferase[J]. J Immunol, 2017,198(7):2626-2639.
[8] Zhang F, Liu G Y, Li D J, et al. DDIT4 and associated lncDDIT4 modulate Th17 differentiation through the DDIT4/TSC/mTOR pathway[J]. J Immunol, 2018, 200(5):1618-1626.
[9] Dang C, Han B, Li Q, et al. Up-regulation of PGC-1alpha in neurons protects against experimental autoimmune encephalomyelitis[J]. FASEB J, 2019, 33(12):14811-14824.
[10] Li M S, Li Z G, Yao Y, et al. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity[J]. Proc Natl Acad Sci U S A, 2017, 114(3):E396-E405.
[11] Roy-O'Reilly M, McCullough L D. Astrocytes fuel the fire of lymphocyte toxicity after stroke[J]. Proc Natl Acad Sci U S A, 2017, 114(3):425-427.
[12] Han R R, Luo J Y, Shi Y C, et al. PD-L1(programmed death ligand 1) protects against experimental intracerebral hemorrhage-induced brain injury[J]. Stroke, 2017, 48(8):2255-2262.
[13] Li D J, Lang W J, Zhou C, et al. Upregulation of microglial ZEB1 ameliorates brain damage after acute ischemic stroke[J]. Cell Rep, 2018, 22(13):3574-3586.
[14] Han B, Jiang W, Liu H J, et al. Upregulation of neuronal PGC-1alpha ameliorates cognitive impairment induced by chronic cerebral hypoperfusion[J]. Theranostics, 2020, 10(6):2832-2848.
[15] G B D 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet Neurol, 2019, 18(5):459-480.